P-type ATPases transport a wide array of ions, regulate diverse cellular processes, and are implicated in a number of human diseases. However, mechanisms that increase ion transport by these ubiquitous proteins are not known. SPCA1 is a P-type pump that transports Mn 2+ from the cytosol into the Golgi. We developed an intra-Golgi Mn 2+ sensor and used it to screen for mutations introduced in SPCA1, on the basis of its predicted structure, which could increase its Mn 2+ pumping activity. Remarkably, a point mutation (Q747A) predicted to increase the size of its ion permeation cavity enhanced the sensor response and a compensatory mutation restoring the cavity to its original size abolished this effect. In vivo and in vitro Mn 2+ transport assays confirmed the hyperactivity of SPCA1-Q747A. Furthermore, increasing Golgi Mn 2+ transport by expression of SPCA1-Q747A increased cell viability upon Mn 2+ exposure, supporting the therapeutic potential of increased Mn 2+ uptake by the Golgi in the management of Mn 2+ -induced neurotoxicity.
manganese | membrane trafficking | secretion | GPP130 P -type ATPases are ubiquitously expressed proteins that mediate transport of a wide array of cations and phospholipids and thereby regulate diverse cellular processes (1) . The Na + /K + ATPase generates membrane potential in neuronal cells, the sarco/endoplasmic reticulum Ca 2+ ATPase (SERCA) regulates skeletal muscle contraction, the H + /K + ATPase mediates gastric acidification, and lipid flippases transport phospholipids to the outer leaflet of the plasma membrane. P-type pumps share a high degree of sequence, structural and functional similarity, and their varied substrate specificities arise from minor changes in their ionbinding residues. During ion transport, autophosphorylation at an invariant aspartic acid residue in the cytoplasmic domain induces a characteristic conformation change from the E1 state, which has high affinity for the ion, to the E2 state, which has low affinity for the ion (1) (2) (3) (4) . Transport through these pumps is limited by the rate of this conformational change (2) . Devising molecular techniques that can increase ion transport through P-type ATPases will significantly improve our understanding of cellular processes regulated by these pumps and may also contribute to new treatments of diseases related to these processes.
Secretory pathway Ca 2+ ATPase1 (SPCA1) is a Golgi-localized P-type ATPase, which pumps Ca 2+ from the cytosol into the Golgi and plays an important role in regulating Ca 2+ homeostasis in mammalian cells (5) . Haploinsufficiency of SPCA1 results in the development of Hailey-Hailey disease, a blistering dermatosis associated with increased cytosolic Ca 2+ levels and impaired Ca 2+ signaling in keratinocytes (5) (6) (7) . Whereas much attention has been focused on its Ca 2+ transport activity, SPCA1 can also transport Mn 2+ into the Golgi with the same affinity as Ca 2+ (4, 8) . The Mn 2+ transport activity of SPCA1 is particularly important because mechanisms regulating Mn 2+ homeostasis in mammalian cells are unknown. Furthermore, whereas Mn 2+ is an essential element required for the catalytic activity of a wide array of enzymes (5) , at elevated levels, Mn 2+ competes with magnesiumbinding sites in proteins, enhances oxidative stress, compromises mitochondrial function, and eventually induces apoptosis (5, 9-11).
The cytotoxic effects of Mn 2+ result in the development of manganism, a Parkinson-like neurodegeneration syndrome, in adults and cognitive and behavioral defects in children (12) (13) (14) . Thus, identifying mechanisms that reduce cytosolic Mn 2+ levels during elevated exposure is of high clinical significance.
Blocking uptake of extracellular Mn 2+ is unlikely to succeed in protecting against Mn 2+ toxicity because, in mammalian cells, extracellular Mn 2+ is transported into the cytosol by multiple ion pumps and channels that belong to different protein families and are not specific for Mn 2+ . However, increasing Mn2 + pumping into the Golgi could potentially reduce cytosolic Mn 2+ levels and thereby protect against toxicity. Unfortunately, the role of the mammalian Golgi in Mn 2+ detoxification has thus far not been tested for three principal reasons. First, compartment-specific subcellular Mn 2+ sensors have not yet been identified, making it impossible to rapidly screen for conditions increasing Mn 2+ transport into the Golgi. Second, the Golgi localization of SPCA1 is saturable and overexpression of the wild-type (WT) protein results in its accumulation in endosomes. Third, as there are no known mechanisms to increase the ion transport through P-type ATPases, it has not been possible to increase the Mn 2+ transport activity of SPCA1.
In the current study we used the predicted structure of SPCA1 to generate mutations that could potentially increase its Mn 2+ pumping activity. Using a unique in vivo Golgi-specific Mn 2+ sensor to rapidly screen for conditions that increase Golgi Mn
2+
, we identified Q747A as a point mutation that increased the Mn 2+ transport activity of SPCA1. Analysis indicated that the structural basis for the enhanced activity of SPCA1-Q747A was increased size of its ion permeation cavity revealing, an unexpected contribution of ion permeation to the overall rate of transport through a P-type ATPase. Furthermore, expression of SPCA1-Q747A protected cells from the cytotoxic effects of Mn 2+ , indicating that conditions increasing Mn 2+ transport into the Golgi may be therapeutically useful in the management of manganism.
Results

Golgi Phosphoprotein of 130 kDa (GPP130) is an Intra-Golgi Mn
2+
Sensor. To rapidly screen for conditions that increased Golgi Mn 2+ uptake in vivo, we needed a sensor that specifically responded to increased Mn 2+ within the Golgi lumen. Although compartment-specific Mn 2+ sensors have not been described, we recently reported that exposure of cells to as low as 100 μM of Mn 2+ induces the cis-Golgi glycoprotein, GPP130, to traffic from the Golgi to multivesicular bodies (MVBs) and then to lysosomes, where it is degraded (15) . This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. E-mail: linstedt@cmu.edu.
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the Golgi marker giantin. To test whether this response was triggered by an increase in Mn 2+ in the Golgi lumen, we depleted SPCA1 to block transport of Mn 2+ from the cytoplasm into the Golgi. Knockdown of SPCA1 abolished the Mn 2+ -induced redistribution and degradation of GPP130 ( Fig. 1 B-D) . Gene replacement with full-length SPCA1 restored the Mn 2+ response of GPP130, whereas replacement with a mutated version defective in autophosphorylation (D350A) and thus unable to transport either Mn 2+ or Ca 2+ (2, 16) did not ( Fig. 1 E and F) . Furthermore, replacement with SPCA1 containing a mutation (G309C) that blocks Mn 2+ but not Ca 2+ pumping activity (4) also failed to rescue the Mn 2+ response of GPP130 ( Fig. 1 E and F) . Thus, the Mn 2+ -induced degradation of GPP130 required a specific increase in intra-Golgi Mn 2+ levels, indicating that GPP130 could be used to screen for conditions that increase Golgi Mn 2+ .
Identification of SPCA1-Q747A as a Potential Hyperactive Mn
Transporter. We first tested whether overexpression of SPCA1-WT increased Golgi Mn 2+ uptake. However, the Golgi localization of SPCA1 was saturable and the level of pump activity increased by WT overexpression did not detectably enhance GPP130 degradation when compared with untransfected cells ( Fig. 2A) . Another possibility was to increase the Mn 2+ pumping activity of SPCA1. A mutation was created (Q747A) to reduce the side chain size of a residue predicted to line the Mn 2+ permeation cavity (see below) as this might improve access of Mn 2+ ions to the ion-binding site in SPCA1. Remarkably, expression of SPCA1-Q747A induced GPP130 degradation even in the absence of externally added Mn 2+ ( Fig. 2 A and B) , suggesting a hyperactivated pump. Degradation of GPP130 was confirmed by immunoblot and the loss induced by SPCA1-Q747A corresponded to the transient transfection frequency (Fig. 2C) . To test whether SPCA1 triggered the GPP130 response due to its Mn 2+ pumping activity, we introduced into SPCA1-Q747A mutations that block pump activity (D350A) or block Mn 2+ but not Ca 2+ transport (G309C) and observed that these mutations blocked its ability to induce GPP130 degradation (Fig. 2 A and B) . Although endogenous SPCA1 was present in these experiments, it was not required as loss of GPP130 induced by SPCA1-Q747A was also observed in cells lacking endogenous SPCA1 due to knockdown (Fig. S1 ).
SPCA1-Q747A expression did not affect Golgi morphology or alter the localization and level of other tested Golgi proteins ( Fig. S2 A-D) . We also confirmed that SPCA1-Q747A did not alter protein trafficking between the Golgi and the endocytic or secretory pathways. Treatment of cells with monensin to block endosome-to-Golgi protein trafficking causes rapid endosomal accumulation of Golgi protein of 73 kDa (GP73), which constitutively cycles between the Golgi and endosomes (17) . The level of the monensin-induced endosomal accumulation of GP73 did not differ between cells that expressed SPCA1-Q747A and those that did not (Fig. S2 E-G) . Additionally, expression of SPCA1-Q747A did not alter the distribution or localization of LAMP-2 ( Fig. S2 H-J) , a protein that traffics to lysosomes from the Golgi (18) . Finally, we analyzed endoplasmic reticulum-to-surface trans- , normalized to tubulin, in cells transfected with control or anti-SPCA1 siRNAs (mean ± SE; n = 3; P < 0.05). (E) Cells treated with anti-SPCA1 siRNA for 48 h were transfected with RNA-resistant HA-tagged SPCA1-WT or mutated constructs. After 24 h they were exposed to 500 μM of Mn 2+ for 4 h and imaged to detect SPCA1 using an anti-HA antibody and GPP130. After Mn 2+ , GPP130 was lost in cells expressing SPCA1-WT but not D350A or G309C (single asterisk). Knockdown cells not transfected with SPCA1-WT did not exhibit a GPP130 Mn 2+ response (double asterisk). (Scale bar, 10 μm.) (F) Quantitation of percentage of transfected cells that did not have detectable GPP130 after Mn 2+ from E (mean ± SE; n = 100 cells per experiment from three independent experiments; P < 0.05). (mean ± SE; n = 100 cells per experiment from six independent experiments; P < 0.05). (C) HeLa cells were transfected with HA-tagged SPCA1-WT or Q747A and harvested 24 h posttransfection as described previously (15) . Immunoblotting was performed to detect GPP130, HA, and tubulin.
port of the temperature-sensitive mutant of vesicular stomatitis virus G protein (VSVG) tagged with GFP (19, 20) . VSVG-GFP trafficking in cells expressing SPCA1-Q747A was indistinguishable from controls, in each case reaching the Golgi in 20 min and the cell surface in 60 min (Fig. S3) .
We also determined that SPCA1-Q747A induced GPP130 degradation by the pathway we previously described for Mn 2+ -induced GPP130 degradation (15) . Upon SPCA1-Q747A expression, GPP130 trafficked to peripheral punctae that overlapped with Rab7, a marker for MVBs, and LAMP-2 before degradation ( Fig. S4 A and B) . GPP130 was also detected within the lumen of giant MVBs induced by coexpression of Rab5-Q79L (Fig. S4C) . Coexpression of dominant negative Rab7 (Rab7-T22D), which inhibits MVB-to-lysosome trafficking, blocked the GPP130 degradation, whereas dominant negative Rab5 (Rab5-S34N), which blocks early endosome-to-MVB trafficking, did not ( Fig. S4 D-F) . In cells coexpressing SPCA1-Q747A and Rab7-T22D, GPP130 accumulated in large peripheral punctae (Fig. S4 D-F) , consistent with our previous description of the retention of GPP130 in an enlarged MVB compartment in Mn 2+ -treated cells expressing Rab7-T22D (15) . Thus, using GPP130 as an intra-Golgi Mn2 + sensor, we identified SPCA1-Q747A as a potentially hyperactive Mn2 + transporter.
Substitution of Q747 with Alanine Increases Activity of SPCA1 by
Increasing the Size of the Ion Permeation Cavity. SPCA1 is >70% similar to SERCA in its transmembrane domains (21) . Mutagenesis and computational modeling of SPCA1 on the basis of the known SERCA structure (22) (23) (24) (25) indicate that SPCA1 has a single ion-binding site located between the fourth and sixth transmembrane domains (M4 and M6) and formed by E-308, N-738, and D-742 (2, 4, 26) (Fig. 3A) . The most likely route for ions to reach this site is through the cavity between M4 and M6. Indeed, this route is taken by hydrated Ca 2+ to reach a similarly positioned ion-binding site in SERCA (22) and mutations in residues of M4 and M6 block access of ions to the homologous ion-binding site in Pmr1p (21, 27, 28) . Residue Q747 of SPCA1 is predicted to be at the cytoplasmic/membrane interface of M6 with an orientation that projects its side chain into the solvent accessible cavity between M4 and M6 ( Fig. 3 A-C) . On the basis of our modeling of SPCA1, the minimum distance or gap between M4 and M6 at this ion entrance point, occurring between V313 on M4 and Q747 on M6, was 3.89 Å (Fig. 3D ). Analysis of a recomputed structure of SPCA1 containing the Q747A substitution confirmed that the side chain volume of residue 747 projecting into the cavity was reduced (Fig. 3E) . As a consequence, the corresponding distance between M4 and M6 increased to 7.0 Å and the apparent minimum distance in the ion permeation cavity, which now occurred between V313 and G743, was 4.86 Å (Fig. 3E) . The increase in gap between M4 and M6 induced by the Q747A substitution is significant in comparison to the ∼1.6Å diameter of a hydrated Mn 2+ ion (29) and could significantly increase the rate at which Mn 2+ reaches the ion-binding site and thus enhance overall pumping activity of SPCA1. Indeed, rate increases are observed in potassium channels containing mutations that increase the size of their transport cavities (30, 31) .
As a test of whether the increase in distance between M4 and M6 caused the gain-of-function observed in SPCA1-Q747A, we attempted to restore the WT distance in SPCA1-Q747A by substituting isoleucine for V314 on M4. According to our modeling of SPCA1, the V314I substitution rotated the side chain of V313 bringing it to within 3.6 Å of G743 on M6 and created a minimum gap similar to WT (Fig. 3F) . In contrast to the strong response of GPP130 to SPCA1-Q747A, the construct containing the compensatory mutation, SPCA1-Q747A+V314I, failed to induce GPP130 degradation ( Fig. 3 G and H) . This could not be attributed to a loss of activity because SPCA1-Q747A+V314I rescued the Mn 2+ response of GPP130 in cells lacking endogenous SPCA1 due to knockdown ( Fig. S5 A and B) . As the V314I substitution suppressed the Q747A phenotype without reintroducing a polar side chain, it suggests that it is increased gap Fig. 3 . The Q747A substitution increases the size of the SPCA1 ion permeation cavity. (A-C) SPCA1-WT was modeled using the MODBASE server as described in Materials and Methods. The M4 and M6 transmembrane domains are depicted in cartoon (A), surface (B), and ribbon (C) forms using the open source PyMol software. Ion-binding residues, E308, N738, and D742 are depicted in red; residue Q747 is in green; and V313 is in blue. Arrowheads indicate the path used by ions to reach the ion-binding site. (D-F). Distances across the ion permeation cavity are shown for the computed structures of SPCA1-WT, SPCA1-Q747A, and SPCA1-Q747A+V314I. Distances between M4 and M6 were measured using the "Measurement Wizard" in PyMol and the structures of the SPCA1 mutants were obtained using the "Mutagenesis Wizard" of PyMol. Blue arrowhead in F shows the rotation of the side chain of V313 after the V314I substitution. Black arrowheads indicate the likely path traversed by ions en route to the ion-binding site. (G) HeLa cells were transfected with HA-SPCA1-Q747A or HA-SPCA1-Q747A+V314I and imaged 24 h later to detect GPP130 and HA. GPP130 was degraded in cells transfected with SPCA1-Q747A but not in those expressing the V314I mutation (single asterisk). Untransfected cells in the SPCA1-Q747A transfected culture exhibited Golgi-localized GPP130 (double asterisk). (Scale bar, 10 μm.) (H) Quantitation of percentage of transfected cells lacking detectable GPP130 from G above (mean ± SE, n = 50 cells from four independent experiments, P < 0.05).
distance and not absence of partial charge that determines the ability of SPCA1-Q747A to increase Golgi Mn 2+ .
Q747A Mutation Increases Mn
2+ Pumping Activity of SPCA1. To directly test whether the Q747A mutation hyperactivated SPCA1, we performed an in vitro 54 Mn 2+ uptake assay on Golgi membranes isolated from cells expressing SPCA1-WT and SPCA1-Q747A. Immunoblotting confirmed recovery of comparable levels of SPCA1-WT and SPCA1-Q747A in the respective pooled Golgi membranes (Fig. 4A) and uptake of 54 Mn 2+ was specific as it was effectively competed by excess nonradioactive Mn 2+ (Fig.  4B) . Significantly, uptake of 54 Mn 2+ was >80% higher in the Golgi vesicles containing SPCA1-Q747A (Fig. 4B) , indicating increased pump activity. These assays lacked Ca 2+ , thus increased Mn 2+ transport was not due to blocked Ca 2+ access to the ionbinding site. Indeed, uptake of 54 Mn 2+ in SPCA1-Q747A containing Golgi vesicles was effectively competed by excess nonradioactive Ca 2+ (Fig. S6A) . Uptake was also carried out in permeabilized cells and again 54 Mn 2+ uptake was specific (Fig.  4C ) and the presence of SPCA-Q747A conferred a twofold increase (Fig. 4D) (Fig. 4G ). The release of 54 Mn 2+ was blocked by pretreatment of the cells with brefeldin A, a fungal metabolite that blocks secretion (Fig. 4 F and G (Fig. S6B) , which is in accord with previous observations of rapid 54 Mn 2+ efflux (32) . Efflux of 54 Mn 2+ was inhibited by blocking transport of Mn 2+ into the Golgi via knockdown of SPCA1 (Fig. S6C) and by transferring cells to 20°C (Fig. 4H) , a temperature that blocks Golgi-to-plasma membrane trafficking (33) . These observations indicate that efflux of intracellular Mn SPCA1-Q747A Increases Cell Viability During Mn 2+ Toxicity. On the basis of the finding that SPCA1-Q747A sequestered and then secreted more Mn 2+ , we tested whether expression of this construct protected cells exposed to toxic levels of Mn 2+ . A doseresponse was carried out on control cells, indicating that exposure to 1 mM of Mn 2+ for 16 h reduced viability by ∼70% (Fig. 5A ). Using this condition, the viability of cells expressing SPCA1-WT or Q747A was compared with control transfected cells. Cells expressing SPCA1-Q747A exhibited a 70% greater survival rate than those expressing the WT protein (Fig. 5B) . The magnitude of increased viability was comparable to that of increased Mn 2+ transport by SPCA1-Q747A. Furthermore, SPCA1-WT, which failed to increase Mn 2+ transport (Fig. 4) , also did not increase viability (Fig. 5B) . On the other hand, knockdown of SPCA1, which reduced Mn 2+ efflux, reduced cell viability by ∼70%, highlighting the crucial role of Golgi Mn 2+ uptake in mediating Mn 2+ detoxification (Fig. 5C ). To confirm the protective effect of Q747A on a cell-by-cell basis, control and Mn 2+ -treated cells were imaged to identify transfected cells and score their viability. Untreated cells expressing SPCA1-WT or Q747A, as indicated by a transfection marker, were healthy in appearance and negative for staining with propidium iodide, which is excluded by viable cells (Fig. 5D ). In contrast, most Mn 2+ -treated cells expressing SPCA1-WT exhibited perturbed morphologies and were inviable, on the basis of propidium iodide staining (Fig. 5 D and E) . Significantly, a large protective effect was again evident for SPCA1-Q747A as ∼60% of cells expressing this construct remained healthy looking and viable (Fig. 5 D and E) . The protective effect of SPCA1-Q747A was also confirmed in the neuronal PC-12 cell line (Fig. S7) . Finally, to determine whether, after uptake into the Golgi, secretion of Mn 2+ was essential for detoxification, the toxicity assay was performed at 20°C to block secretion and, as shown above, Mn 2+ efflux. Cell viability was unaffected at 20°C in 
Mn
2+ by isolated Golgi vesicles was performed as described in Materials and Methods. Uptake was normalized to the uptake by untransfected cells (set to 100) and the experiment was replicated three times (mean ± SE; P < 0.05 for the difference in uptake in untransfected cells with and without excess cold Mn 2+ and for the difference in uptake between SPCA1-WT and Q747A). (C) Uptake of 54 Mn 2+ in permeabilized cells was done as described in Materials and Methods. Uptake in absence of cold Mn 2+ was normalized to 100 for each experiment (mean ± SE, n = 3, P < 0.05). (D) Uptake of 54 Mn 2+ on FACS sorted cells expressing either GFP alone or GFP and SPCA1-WT or GFP and Q747A was performed as in C above. Uptake in cells expressing GFP alone (set to 100) was used for normalization (mean ± SE, n = 3, P < 0.05 for the difference between SPCA1-WT and Q747A). (E) Cells were loaded with 54 Mn 2+ and intracellular radioactivity was measured at various time points. Uptake at 30 min (set to 100) was used for normalization (mean ± SE, n = 3, P < 0.05). (F) Control or BFA-treated cells were loaded with 54 Mn 2+ for 30 min, washed, and chased for 30 min. Intracellular radioactivity after a 30-min loading was normalized to 100 for control and BFA (mean ± SE, n = 3, P < 0.05 for the difference in intracellular radioactivity retained after the chase in control cultures). (G) Distribution of intracellular and extracellular radioactivity after a 30-min chase in the presence or absence of BFA. (H) Cells were loaded with 54 Mn 2+ for 30 min at 37°C, washed, and chased for 30 min at 37°C or 20°C. Intracellular radioactivity after a 30-min loading was normalized to 100 (mean ± SE, n = 3, P < 0.05 for the difference in intracellular radioactivity retained between 37°C and 20°C groups). (I and J) FACS sorted cells expressing SPCA1-WT or Q747A were loaded with 54 Mn 2+ for 30 min and subsequently chased for an additional 30 min. Intracellular radioactivity retained and secreted after the 30-min chase was normalized to 50 for WT-expressing cells (mean ± SE, n = 3, P < 0.05 for the difference in radioactivity retained and radioactivity secreted between WT and Q747A).
the absence of Mn 2+ but, after exposure to Mn 2+ , the protective effect of SPCA1-Q747A was no longer evident (Fig. 5F) . Thus, Mn 2+ efflux via uptake by the Golgi and secretion is essential for Mn 2+ detoxification and increasing Mn 2+ transport into the Golgi protects against Mn 2+ -induced cytotoxicity (Fig. 5G ).
Discussion
Mutations inhibiting transport through P-type pumps are often described but gain-of-function mutations are not. After confirming that the previously described Mn 2+ -induced trafficking and degradation of GPP130 (15) requires a specific increase in intra-Golgi Mn, we used GPP130 as a sensor of intra-Golgi Mn 2+ and identified Q747A as a hyperactivating mutation of SPCA1. Structural modeling indicated that the Q747A substitution increased ion permeation to the binding site, which is significant because the rate of conformational change between the E1 and E2 states is considered rate limiting for P-type ATPases (2). It is unlikely that the Q747A substitution directly influenced the rate of this conformational change because Q747 does not appear to interact with neighboring residues in any of the SPCA1 conformations computationally determined on the basis of SERCA. A more likely possibility, based on the compensatory mutation, is that access to the ion-binding site is partially impeded by Q747 and reducing the size of Q747 allows quicker reloading of the pump when it reverts back to the E1 conformation.
There are a few known mutations of P-type ATPases that increase activity but these mutations relieve negative regulation to restore constitutive activity (34) (35) (36) . The best-characterized example is for plasma membrane calcium ATPase (PMCA), which has an autoinhibitory domain that binds calmodulin (35, 36) . Deletion of this domain increases Ca 2+ transport to the level normally seen when calmodulin binds and counteracts the effect of the inhibitory domain (36) .
Enlargement of the ion access cavity may be a generally applicable strategy to increase the intrinsic rates of P-type ATPases. Sequence alignments indicate that residues with bulky side chains are present at the entrance face of ion permeation cavities of other P-type pumps. Residues corresponding to Q747 of SPCA1 include T804 in SERCA and L888 in PMCA4. Conceivably, alanine substitution at these sites could hyperactivate the pumps. However, success in increasing pump activity would also depend on the nature of the other residues lining the cavity. For example, a mutation homologous to Q747A in the yeast homolog of SPCA1, Pmr1p (the mutation in Pmr1p is Q783A), blocks rather than increases Mn 2+ transport (21, 27) . This difference in activity likely occurs because, in contrast to the valine at 313 opposite Q747 in SPCA1, Pmr1p has an isoleucine in this position. The bulkier side chain of isoleucine may alter helix packing when present opposite the alanine residue in Pmr1p-Q783A and thereby occlude access of Mn 2+ to the ion-binding site (21, 27) . Thus, although using the SERCA structure to target the ion access gateway of other P-type ATPases is now an exciting possibility, careful attention will need to be paid to differences in neighboring residues.
Increased Mn 2+ transport into the Golgi by SPCA1-Q747A protected cells against Mn 2+ -induced cytotoxicity, whereas blocking Mn 2+ transport into the Golgi or out of the Golgi to the cell surface had the opposite effect, showing the importance of the Golgi apparatus in Mn 2+ homeostasis and detoxification in mammalian cells. Consistent with our results, HEK293 cells, which express low levels of endogenous SPCA1 (2), were recently shown to be sensitive to Mn 2+ and protected from toxicity by SPCA1 expression (37) . The identification of the Golgi as the major route of Mn 2+ detoxification is significant, given that Mn 2+ efflux via bile is the sole mechanism for Mn 2+ excretion in humans, and patients with compromised liver function due to diseases like cirrhosis develop Mn-induced neurotoxicity without exposure to elevated Mn 2+ (38) . These results are also consistent with the Mn 2+ hypersensitivity of ΔPMR1 yeast strains (39) but, without a hyperactive Mn 2+ pump, earlier investigations were unable to address whether increasing Mn 2+ uptake into the Golgi offered any protective effect. Our findings reveal that increased Golgi Mn 2+ uptake actually leads to less Mn 2+ retention by cells due to secretion. Thus, increased pumping into the Golgi likely alters ion flux such that, at least within a particular concentration range of extracellular Mn 2+ , efflux of Mn 2+ becomes greater than influx.
Our results highlight the therapeutic potential of increasing cytosol-to-Golgi Mn 2+ transport in the management of manganism, a disease that remains incurable. Clearly, gene therapy with SPCA1-Q747A is not easily feasible, but a promising avenue is a drug targeting the machinery responsible for SPCA1 locali- 2+ for 16 h and viability was determined using the MTT assay. Controls were untreated (0 mM of Mn 2+ ). Samples were normalized using absorption at 570 nm of the controls (set to 100) for each experiment (mean ± SE, n = 3, P < 0.05). (B) FACS sorted cells expressing GFP alone, GFP and SPCA1-WT, or GFP and SPCA1-Q747A were left untreated or exposed to 1 mM of Mn 2+ for 16 h and viability was determined using the MTT assay. Viability in cells expressing GFP alone (set to 100) was used for normalization (mean ± SE, n = 3, P < 0.05 for the difference in viability between SPCA1-WT and Q747A). (C) Cells were treated with control or anti-SPCA1 siRNAs for 48 h and then exposed to 0 or 1 mM of Mn 2+ for 16 h. Cell viability was assessed using the MTT assay and viability in cells treated with the control siRNA (set to 100) was used for normalization (mean ± SE, n = 3, P < 0.05 for the difference in viability between control and anti-SPCA1 siRNA treated groups). (D) Cells were transfected with SPCA1-WT or Q747A and mCherry for 24 h and then exposed to 1 mM of Mn 2+ for 16 h. Propidium iodide staining was performed as described in Materials and Methods. (Scale bar, 10 μm.) (E) Quantitation of percentage of transfected cells positive for propidium iodide from D above (mean ± SE, n = 25 cells from three independent experiments per group, P < 0.05 for the difference between SPCA1-WT and Q747A after Mn 2+ ). (F) Cells were transfected with a GFP marker alone or cotransfected with GFP and SPCA1-WT or Q747A for 24 h and then exposed to 1 mM of Mn 2+ for 16 h at 20°C. Control cultures did not receive Mn 2+ . Cell viability was then assayed using propidium iodide staining (mean ± SE, n = 25 cells from three independent experiments per group, P > 0.05 for the difference in cell viability between GFP, SPCA1-WT, and Q747A after Mn 2+ and P < 0.05 for the difference in cell viability with and without Mn 2+ in the GFP group zation in the Golgi. We observed that Golgi targeting of SPCA1 is readily saturated leading to endosome localization. Interestingly, a pool of endosomal SPCA1 has recently been detected in bile canalicular WIF-B cells (37) , suggesting that SPCA1 in a physiologically relevant cell type may already be expressed in excess of that required for Golgi saturation. Thus, preventing SPCA1 exit from the Golgi in these cells should protect against Mn 2+ toxicity. In conclusion, we have elucidated an unexpected mode of hyperactivating the pumping activity of a P-type ATPase and demonstrated that increased Mn 2+ pumping into the Golgi protects mammalian cells from the cytotoxic effects of Mn 2+ .
Materials and Methods
Cell culture, transfections, immunofluorescence microscopy, image analysis, and immunoblot analyses were done as described by us previously (15, 19, 20, 40, 41) . Tertiary structure of SPCA1 was derived using the algorithms of the MODBASE server (http://modbase.compbio.ucsf.edu/modbase-cgi/index. cgi; ref. 42) . Purification of Golgi membranes on discontinuous sucrose gradients was done essentially as described (43, 44) . The in vitro uptake of 54 Mn 2+ in pooled Golgi membranes was done as described (16) . To ensure 100% transfection frequency of SPCA1-WT or Q747A in a transient transfection system, cells were cotransfected with SPCA1-WT or Q747A and Rab5-GFP-WT and sorted using fluorescence-activated cell sorting (Vantage SF; Becton Dickinson) in the GFP channel. FACS sorted cells were used for uptake assays using permeabilized cells and for the viability assays using methylthiazolylphenyl-tetrazolium bromide (MTT). Uptake of 54 Mn 2+ in permeabilized cells was done as described (4, 45) . MTT assay was performed as described (15) . Propidium iodide was from Sigma-Aldrich and was used as described by the manufacturer. See SI Materials and Methods for details.
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SI Materials and Methods
Cell Culture, Transfections, Immunofluorescence Microscopy, Image Analysis, and Immunoblot Analyses. Unless otherwise specified, these procedures were done as described by us recently (1). For Mn 2+ treatment, freshly prepared MnCl 2 was added to the medium at the concentrations indicated in the figure legends (1) . Small interfering RNA (siRNA) against SPCA1 targeted the sequence 5′-AAGGTTGCACGTTTTCAAA AA-3′ in the SPCA1 cDNA. We have previously characterized the control siRNA (2, 3) . The SPCA1-replacement constructs had three silent mutations in the sequence targeted by the siRNA (1, 2) . These silent mutations were introduced using the forward primer 5′-GG-TGGTGGTGGTG GGTTAATTAAGAAGGTCGCCCG GTT-TCAAAAAAT ACCTAATGG-3′. The mutated bases in the replacement construct are underlined.
Constructs. HA-tagged SPCA1-WT construct was from Rajini Rao (The Johns Hopkins Medical School, Baltimore, MD). Point mutations in SPCA1-WT were introduced using QuikChange mutagenesis kit (Strategene) and confirmed by sequencing. Substitution of the HA-tag with a single myc epitope was done using a loop-out/loop-in modification of the QuikChange protocol. GFP-tagged Rab5-WT, Rab5-S34N, Rab5-Q79L, Rab7-WT, and Rab7-T22D constructs used in this study have been described by us previously (1).
Tertiary Structure of SPCA1. Tertiary structure of SPCA1 was derived using the algorithms of the MODBASE server (http:// modbase.compbio.ucsf.edu/modbase-cgi/index.cgi; ref. 4) on the basis of homology with SERCA (5).
Preparation of Golgi Membranes by Sucrose Gradient Flotation. Purification of Golgi membranes was done essentially as described previously (6, 7) . HeLa cells from five 10-cm plates were harvested in cold PBS (1 mL per plate) and cells were pelleted by centrifugation at 1,040 rpm for 2 min. The pellet was transferred to 400 μL of homogenization buffer (0.25 M sucrose, 1 mM TrisCl; pH 7.4, 1 mM EDTA) and passed through a 25-gauge needle ∼50 times. The postnuclear supernatant (PNS) was obtained by centrifugation at 2,500 rpm for 3 min. The PNS was adjusted to 1.6 M sucrose and loaded on a step gradient consisting of cushion of 2 M sucrose at the bottom (1.1 mL), overlaid sequentially with 1.1 mL of the 1.6-M load, 1.1 mL of 1.2 M sucrose, and 0.55 mL of 0.8 M sucrose. Sucrose solutions used in the gradient contained 10 mM Tris-Cl; pH 7.4, and 1 mM MgCl 2 . The gradient was spun in a Sw50.1 rotor (Beckman Coulter) at 38,000 rpm for 4 h at 4°C. Fractions at the 0.8 M/1.2 M sucrose interface containing the Golgi membranes were pooled, resuspended in 4 mL of 0.25 M sucrose, 10 mM Tris-Cl; pH 7.4 and 1 mM MgCl 2 and sedimented by spinning in the Sw50.1 rotor at 38,000 rpm for 30 min at 4°C. The Golgi membrane pellet obtained was then resuspended at a final protein concentration of 0.1 mg/mL in 0.25 M sucrose, 10 mM Hepes; pH 6.7, 150 mM KCl, 5 mM NaN 3 , 5 mM MgCl 2 .
Golgi 54 Mn 2+ Transport Assay. The in vitro uptake of 54 Mn 2+ into Golgi vesicles was done as described previously (8) . Pooled Golgi membranes (10 μL), corresponding to 1 μg of protein, were added to 50 μL of transport buffer [10 mM Hepes; pH 6.7, 150 mM KCl, 5 mM NaN 3 , 5 mM MgCl 2, 25 μM carbonyl cyanide 3-chlorophenylhydrazone (CCCP), 1 mM ATP, 1.6 μCi/mL , respectively. Uptake was carried out for 5 min at room temperature. The reaction was stopped by transferring the tubes to ice and adding 60 μL of stop buffer (10 mM Hepes; pH 9.0, 150 mM KCl, 10 mM EDTA). Golgi vesicles were retrieved by spinning at 15,000 rpm on a tabletop centrifuge for 10 min at 4°C. We confirmed, by immunoblot, that we could effectively recover all of the input Golgi membranes with this spin. The supernatant was discarded and the pelleted membranes were gently washed two times in 100 μL of stop buffer and subsequently lysed in 100 μL of lysis buffer (1% Triton X-100, 0.1 N HCl in isopropanol). Radioactivity was then measured using the LS6500 liquid scintillation counter (Beckman Coulter).
Fluorescence-Activated Cell Sorting (FACS). To obtain identical numbers of cells with nearly 100% transfection of SPCA1-WT or Q747A in a transient transfection system, we cotransfected cultures with a GFP-tagged construct (Rab5-WT) and SPCA1-WT or Q747A. One day after cotransfection, identical numbers of GFP positive cells were sorted for each group using FACS (Vantage SF; Becton Dickinson). We obtained >98% cotransfection of Rab5 and the SPCA1 constructs and verified that expression of Rab5-WT-GFP did not alter the localization of SPCA1-WT or Q747A. Further, the expression levels of SPCA1-WT and Q747A were similar to each other and GPP130 was degraded in cotransfected cells expressing the Q747A mutant but not WT. FACS sorted cells were used for 54 Mn 2+ uptake assays in permeabilized and intact cells and for Mn 2+ toxicity experiments.
54
Mn 2+ Uptake in Permeabilized Cells. Uptake of 54 Mn 2+ in permeabilized cells was done essentially as described previously (9, 10) . For each assay, 8,000 cells were sorted on a coverslip placed in a well of a 24-well plate. One day after sorting, cells were permeabilized for 15 min at room temperature in 30 mM imidazole; pH 6.8, 120 mM KCl, 1 mM MgCl 2 , 1 mM ATP, and 30 μg/mL saponin. Cells were then washed two times with PBS and incubated for 30 min in 30 mM imidazole; pH 6.8, 120 mM KCl, 1 mM MgCl 2 , 5 mM ATP, and 0.5 μCi/mL of 54 Mn 2+ . For competition with nonradioactive Mn 2+ , this buffer was supplemented with 100 μM MnCl 2 . After 30 min, cells were washed two times in PBS+ 10 mM EDTA and harvested in 250 μL of lysis buffer (1% Triton X-100, 0.1 N HCl in isopropanol). Radioactivity was measured by liquid scintillation.
Mn 2+ Import/Export Assays in Intact Cells. As in the permeabilized cell assay, import and export of 54 Mn 2+ was assayed using 8,000 FACS sorted cells. Uptake was performed at 37°C with 0.5 μCi/ mL of 54 Mn 2+ in 500 μL of HBSS with NaHCO 3 without phenol red (Sigma-Aldrich) per coverslip. After uptake, cells were washed two times in PBS+ 10 mM EDTA and either directly harvested (see below) or used for the chase part of the experiment. Before the chase, cells were rapidly washed one more time with 250 μL of PBS (without EDTA) and this wash was collected and used to measure background radioactivity nonspecifically present on the coverslip. Cells were then transferred to 500 μL HBSS without 54 Mn 2+ and incubated for 30 min. After this, the HBSS was collected and the radioactivity obtained from the last PBS wash was subtracted from that obtained in this sample and represented the total radioactivity secreted. To measure intracellular radioactivity, cells were again washed two times with PBS+ 10 mM EDTA and harvested in lysis buffer (1% Triton X-100, 0.1 N HCl in isopropanol). Competition with non-radioactive Mn 2+ was performed with 100 μM MnCl 2 . Where indicated, cells were pretreated with brefeldin A (10 μg/mL, ref. 11) for 15 min before being exposed to 54 Mn 2+ .
Viability Assays. The methylthiazolylphenyl-tetrazolium bromide (MTT; EMD Chemicals) assay was performed using 20,000 FACS sorted cells as described by us previously (1) . Propidium iodide was from Sigma-Aldrich and was used as described by the manufacturer. Briefly, cells were cotransfected with SPCA1-WT or Q747A and a transfection marker (mCherry or GFP-tagged Rab5-WT). One day after transfection, cultures were either exposed to 1 mM Mn 2+ or left untreated. Sixteen hours after exposure to Mn 2+ , cells were washed two times in binding buffer (10 mM Hepes; pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , and 1.8 mM CaCl 2 ) and then incubated in 1% propidium iodide in binding buffer for 15 min at room temperature. At the end of the incubation period, cells were again washed in binding buffer and immediately mounted for microscopy. Images were collected as described previously (12) .
VSVG-GFP Trafficking Assays. Trafficking of VSVG-GFP was analyzed as described earlier (2, 3) . Cells were transfected with VSVG-GFP alone or in combination with SPCA1-Q747A for 24 h and then shifted to 40°C for 16 h. Cultures were then shifted to 32°C for 20, 40, and 60 min. At the end of the time course, cultures were incubated with an antibody against the ectodomain of VSVG (2, 3) on ice for 30 min. Subsequently, cultures were fixed, stained, and imaged.
Antibodies and Chemicals. Polyclonal (pAb) and monoclonal (mAb) antibodies against GPP130, pAb against giantin and GP73, and mAb against myc and VSVG have been described by us (1, 3, 11, 12) . Monoclonal antibodies against HA epitope and tubulin were from Sigma-Aldrich and that against LAMP-2 was from Abcam. All chemicals were from Sigma-Aldrich unless otherwise specified.
Statistical Analyses. Comparison between two groups was performed using two-tailed Student's t test assuming equal variances. Multiple group comparison at the same time was done using single-factor analysis of variance (ANOVA) with the TukeyKramer post hoc test (NCSS 2007 software). Asterisks in the bar graph indicates P < 0.05. Controls were untransfected. Cultures were then exposed to 10 μM of monensin for 30 min, fixed, and stained to detect GPP130 and GP73. (Scale bar, 10 μm.) (F and G) Quantitation of average number of GP73 endosomes per cell and average size of each GP73 endosome in cells expressing SPCA1-Q747A and controls was obtained using the Analyze Particle function of ImageJ (mean ± SE; n = 10 cells per condition; P > 0.05. The experiment was independently replicated three times). (H) HeLa cells were transfected with SPCA1-Q747A for 24 h. Controls were untransfected. Cultures were fixed and stained to detect LAMP-2 and GPP130. (Scale bar, 10 μm.) (I and J) Quantitation of LAMP-2 endosomes was done as described for F and G above (mean ± SE; n = 10 cells per condition; P > 0.05. The experiment was independently replicated three times). Fig. S4 . (A) Cells were cotransfected with Rab7-WT-GFP and HA-SPCA1-Q747A for 24 h and imaged to detect GPP130 and GFP. Cotransfection frequency was >98%. GPP130 was detectable in peripheral punctae only in GFP positive cells. (Scale bar in main panel, 10 μm; scale bar for inset, 2 μm.) (B) Cells were transfected with SPCA1-Q747A and 24 h later imaged to detect LAMP-2 and GPP130. (Scale bar, 2 μm.) (C) Cells were cotransfected with Rab5-Q79L and SPCA1-Q747A for 24 and imaged to detect GPP130 and GFP. Note that transfection of Rab5-Q79L alone does not target GPP130 to Rab5-MVBs (1). (Scale bar, 10 μm; inset, 2.5×). (D) Cells were cotransfected with HA-SPCA1-Q747A and either Rab5-S34N or Rab7-T22D and imaged 24 h later to detect GFP, HA, and GPP130. Cotransfection was >98%. GPP130 was not detectable in cotransfected cells expressing Rab5-S34N (single asterisk), whereas it remained Golgi localized in untransfected cells in the same culture (double asterisk). Cotransfected cells expressing Rab7-T22D (single asterisk) exhibited large cytoplasmic punctae positive for GPP130. Transfection of the dominant negative Rab constructs by themselves do not alter the localization of GPP130 (1). (Scale bar, 10 μm.) (E) Quantitation of mean GPP130 levels per cell after transfection of Rab5-S34N or Rab7-T22D and SPCA1-Q747A from D above. Mean GPP130 level in Rab5-S34N cells is normalized to 100 (mean ± SE; n = 10 cells from one experiment per group, the experiment was independently replicated three times; P < 0.05). (F) Quantitation of total GPP130 particles per cell in cotransfected cells from D above (mean ± SE, n = 15 cells from one experiment per group, the experiment was replicated three times independently, P < 0.05). Particles were counted using National Institutes of Health Image J as described previously (1). (mean ± SE; n = 50 cells per experiment from three independent experiments; P < 0.05).
Fig. S6. (A) Uptake of
54 Mn 2+ by isolated Golgi vesicles was performed as described in Materials and Methods. To inhibit the activity of SERCA, 10 μM of thapsigargin was included in the transport buffer (13) and uptake was performed in the presence and absence of excess cold Ca 2+ . Uptake in the absence of Ca 2+ was normalized to 100 separately for untransfected, WT, or Q747A and uptake in the presence of Ca 2+ is expressed relative to that for each condition (mean ± SE; n = 3 transport assay; P > 0.05, for the difference in relative uptake between untransfected, WT and Q747A-expressing cells after cold Ca 2+ ). (B) HeLa cells were loaded with 54 Mn 2+ for 30 min, washed, and chased. The supernatant was collected every 10 min. Total 54 Mn 2+ counts released after 30 min was normalized to 100 (mean ± SE; n = 3; P < 0.05). (C) Control or anti-SPCA1 siRNA treated cells were loaded with 54 
Mn
2+ for 30 min, washed, and chased for 30 min. Intracellular radioactivity after a 30-min loading was normalized to 100 for both groups. Radioactivity retained after the 30-min chase is expressed relative to that (mean ± SE, n = 3, P < 0.05 for the difference in intracellular radioactivity retained). The percentage of retention of intracellular Mn 2+ in cultures treated with anti-SPCA1 siRNA is ∼75%, and not closer to 100%, which can be attributed to incomplete knockdown of SPCA1. 
